Key points:
- Tata Medical & Diagnostics could team up with the India’s Council of Scientific and Industrial Research to carry out clinical trials of Moderna’s vaccine candidate in India.
- Unlike Pfizer’s vaccine, which must be kept at minus 70 degrees Celsius or below, Moderna’s can be stored at normal fridge temperatures.
- Data released in November from Moderna’s late-stage study showed it was 94.1% effective with no serious safety concerns.
- India mandates that any vaccine maker must conduct an additional local study.
Tata Medical & Diagnostics could team up with the India’s Council of Scientific and Industrial Research to carry out clinical trials of Moderna’s vaccine candidate in India, the said, citing officials familiar with the matter.
On Monday Tata Group’s healthcare venture is said to have started initial discussions with Moderna Inc for a partnership to launch its COVID-19 vaccine in India.
Unlike Pfizer’s vaccine, which must be kept at minus 70 degrees Celsius or below, Moderna’s can be stored at normal fridge temperatures, making it more suited for poorer countries such as India where cold chains are limited.
Data released in November from Moderna’s late-stage study showed it was 94.1% effective with no serious safety concerns. The shot was approved for use in the United States in December and in Europe earlier this month.
India mandates that any vaccine maker must conduct an additional local study if it has to be considered for what the country calls the world’s biggest vaccination programme.
